Lyell Immunopharma, Inc.

Listed Company

LYELCIK 0001806952NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$36.0K

Net Income

$-274.45M

Total Assets

$340.05M

Equity

$248.20M

Shares Out

23.31M

Op. Cash Flow

$-150.02M

Business

Lyell Immunopharma, Inc. is a clinical-stage cell therapy company developing next-generation autologous chimeric antigen receptor (CAR) T‑cell therapies for hematologic malignancies and solid tumors. Its main products and services comprise proprietary CAR T‑cell product candidates (including the lead dual‑targeting CD19/CD20 program IMPT‑314), T‑cell reprogramming technologies (anti‑exhaustion, durable stemness) and GMP manufacturing protocols. Key business areas include clinical development programs, preclinical research platforms and in‑house manufacturing operations. Lyell conducts clinical trials and manages manufacturing and collaborations primarily in the United States while pursuing global regulatory and commercial opportunities.

Summary from filing dated 2025-03-11

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	36,000	61,000	130,000	85	11
Research and development	159	172	183	159	—
General and administrative	45	52	67	117	89
Other operating income, net	−2	−3	−3	−5	−2
Acquired in-process research and development	66	87	0	0	—
Impairment of long-lived assets	1	51	0	0	—
Total operating expenses	269	359	247	272	225
Loss from operations	−269	−359	−247	−187	−215
Interest income, net	13	24	23	7	1
Other (expense) income, net	−18	5	2	2	−161,000
Impairment of other investments	0	−13	−13	−5	−36
Total other (loss) income, net	−5	16	12	4	−35
Net loss	−274	−343	−235	−183	−250
Net unrealized (loss) gain on marketable securities	−49,000	385,000	8	−6	−2
Comprehensive loss	−274	−343	−227	−189	−252
Net loss per common share, basic (in dollars per share)	−16.06	−26.23	−18.7	−0.74	−1.84
Net loss per common share, diluted (in dollars per share)	−16.06	−26.23	−18.7	−0.74	−1.84
Weighted-average shares used to compute net loss per common share, basic (in shares)	17	13	13	247	136
Weighted-average shares used to compute net loss per common share, diluted (in shares)	17	13	13	247	136

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	60	106	146	124	294
Marketable securities	187	265	401	517	321
Prepaid expenses and other current assets	14	9	8	11	11
Total current assets	261	380	555	651	626
Restricted cash	2	2	284,000	280,000	466,000
Marketable securities, non-current	0	13	17	70	284
Other investments	19	19	32	45	47
Property and equipment, net	35	48	103	123	120
Operating lease right-of-use assets	19	25	40	43	47
Other non-current assets	5	5	4	5	3
Total assets	340	491	750	938	1,127
Accounts payable	3	5	5	4	3
Accrued liabilities and other current liabilities	47	41	28	29	29
Contingent consideration payable	0	8	0	—	—
Total current liabilities	49	54	35	37	47
Operating lease liabilities, non-current	42	51	57	63	67
Other non-current liabilities	517,000	3	4	4	5
Total liabilities	92	108	95	104	198
Commitments and contingencies (Note 18)	—	—	—	—	—
Preferred stock, $0.0001 par value; 10,000 shares authorized at December 31, 2025 and 2024, respectively; no shares issued and outstanding at December 31, 2025 and 2024	0	0	0	0	0
Common stock, $0.0001 par value; 500,000 shares authorized at December 31, 2025 and 2024, respectively; 21,251 and 14,744 shares issued and outstanding at December 31, 2025 and 2024, respectively	2,000	1,000	25,000	25,000	24,000
Additional paid-in capital	1,868	1,728	1,657	1,608	1,516
Accumulated other comprehensive income	242,000	291,000	−94,000	−8	−2
Accumulated deficit	−1,620	−1,345	−1,002	−767	−584
Total stockholders equity	248	383	655	833	930
Total liabilities and stockholders equity	340	491	750	938	1,127

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation expense	42	33	47	82	62
Loss on securities purchase agreement put/call	19	0	0	—	—
Depreciation and amortization expense	12	20	20	18	14
Net amortization and accretion on marketable securities	−5	−15	−10	−930,000	2
Non-cash lease income	−4	−2	−2	−2	911,000
Loss on property and equipment disposals, net	3	1	2	103,000	1
Change in fair value of contingent consideration payable	−2	−4	0	0	—
Change in fair value of success payment liabilities	831,000	−1	−3	−5	4
Impairment of other investments	0	13	13	—	—
Loss (gain) on marketable equity security	30,000	−30,000	0	—	—
Prepaid expenses, other current assets and other assets	3	2	3	−2	−7
Accounts payable	−2	−3	1	667,000	91,000
Accrued liabilities and other current liabilities	−8	−1	−719,000	−463,000	5
Other non-current liabilities	−3	−411,000	−449,000	−453,000	4
Net cash used in operating activities	−150	−162	−164	−170	−126
Purchases of property and equipment	−780,000	−464,000	−3	−24	−66
Sales of property and equipment	287,000	0	0	—	—
Purchases of marketable securities	−279	−395	−477	−406	−673
Maturities of marketable securities	375	549	664	419	617
Acquisition of assets, net of cash acquired	−41	−31	0	0	—
Net cash provided by investing activities	54	122	184	−12	−122
Proceeds from securities purchase agreement equity issuance	50	0	0	—	—
Proceeds from exercise of stock options	42,000	154,000	306,000	10	9
Proceeds from employee stock purchase plan	365,000	1	2	2	0
Taxes paid related to net share settlement of equity awards	−1,000	−76,000	−457,000	−461,000	0
Net cash provided by financing activities	50	1	2	11	401
Net (decrease) increase in cash, cash equivalents and restricted cash	−46	−39	22	−170	153
Cash paid for amounts included in the measurement of lease liabilities	13	11	11	11	9
Equity issued for Acquisition (Note 3)	34	36	0	0	—
Securities purchase agreement put/call issuance	8	0	0	—	—
Equity issued for contingent consideration - ImmPACT Bio USA Inc. acquisition	6	0	0	—	—
Contingent consideration payable related to the purchase of the IPR&D asset on Closing Date (Note 3 & 8)	0	11	0	0	—
Purchases of property and equipment included in accounts payable and accrued liabilities	0	144,000	29,000	1	5

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro